Resmed Inc (RMD) Stock Price & Analysis
Resmed Inc (RMD) fell 0.37% to USD 228.35 as of September 8, 2026 at 11:03 UTC, according to Nexqual real-time market data.
RMD last closed at USD 229.19; the session ranged USD 225.17–228.49 on volume of 837,607 shares. Market capitalization is $32.94B, with a 52-week range of USD 180.27–284.87 (NYQ). Source: Nexqual, September 8, 2026 at 11:03 UTC.
Key Statistics (as of September 8, 2026 at 11:03 UTC)
| Price | USD 228.35 |
|---|---|
| Change | ▼ 0.37% (down) |
| Previous Close | USD 229.19 |
| Open | USD 225.91 |
| Day Range | USD 225.17 – 228.49 |
| 52-Week Range | USD 180.27 – 284.87 |
| Volume | 837,607 shares |
| Market Cap | $32.94B |
| Exchange | NYQ |
Technical Analysis (RMD)
Nexqual's technical model rates RMD "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 11:03 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 56.49 (neutral) |
| vs SMA50 | Above (USD 215.28) |
| MACD | 5.06 (positive) |
Analyst Ratings (RMD)
Wall Street analysts rate RMD "Buy" based on 16 analysts, with a mean price target of USD 246.13 (range USD 175–320), per Nexqual as of September 8, 2026 at 11:03 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 246.13 |
| High Target | USD 320 |
| Low Target | USD 175 |
| Buy / Hold / Sell | 7 / 11 / 1 |
Earnings (RMD)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 2.69 |
| Revenue Estimate | $1.39B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.95 vs est 2.89 ▲ beat |
| 2026-03-31 | USD 2.86 vs est 2.8 ▲ beat |
| 2025-12-31 | USD 2.81 vs est 2.72 ▲ beat |
| 2025-09-30 | USD 2.55 vs est 2.5 ▲ beat |
Source: Nexqual, September 8, 2026 at 11:03 UTC.
Financials & Fundamentals (RMD)
| Total Revenue | $5.65B |
|---|---|
| Revenue Growth (YoY) | +8.60% |
| Gross Margin | +61.62% |
| Operating Margin | +30.86% |
| Profit Margin | +26.95% |
| ROE | +24.27% |
| Debt / Equity | 12.54 |
| Current Ratio | 3.1 |
| Total Cash | $1.47B |
| Total Debt | $825.92M |
| Free Cash Flow | $939.25M |
Source: Nexqual, September 8, 2026 at 11:03 UTC.
Financial Health Score (RMD)
Nexqual rates Resmed Inc's overall financial health "Strong" across five dimensions, as of September 8, 2026 at 11:03 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 62%, operating 31% |
| Balance Sheet | Strong — $1.47B cash vs $826M debt, net cash position |
| Cash Flow | Strong — FCF $939M, 17% margin |
| Efficiency | Strong — ROE 24%, ROA 14.0% |
Ownership (RMD)
| Insider Ownership | +0.50% |
|---|---|
| Institutional Ownership | +71.41% |
| Shares Outstanding | 144.25M |
| Float | 143.37M |
| Short % of Float | +10.23% |
Source: Nexqual, September 8, 2026 at 11:03 UTC.
Leadership (RMD)
Resmed Inc is led by Michael J. Farrell BE, MBA, SM (age 53), CEO & Chairman, per Nexqual as of September 8, 2026 at 11:03 UTC.
| CEO & Chairman | Michael J. Farrell BE, MBA, SM (age 53) |
|---|---|
| Founder, Chair Emeritus & Non-Executive Director | Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD (age 83) |
| Chief Product Officer | Justin Leong (age 47) |
| Chief Financial Officer | Aaron Bloomer (age 39) |
| Chief Marketing Officer | Yvonne-Katrin Pucknat (age 49) |
Major Backers & Investors (RMD)
Notable institutional backers of Resmed Inc include First Trust Advisors LP, Invesco, Morgan Stanley, according to Nexqual as of September 8, 2026 at 11:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Trust Advisors LP | 1.58% |
| Invesco | 1.43% |
| Morgan Stanley | 1.34% |
| Fidelity | 1.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 22.1% |
| BlackRock | 9.92% |
| State Street | 5.87% |
| Geode Capital | 3.02% |
| BNY Mellon | 2.91% |
| Northern Trust | 1.18% |
Source: Nexqual, September 8, 2026 at 11:03 UTC.
From Resmed Inc's Latest SEC 10-K Filing (filed 2026-08-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Another study published in Lancet Respiratory Medicine in 2019 estimated that mild to severe OSA impacts more than 936 million people worldwide, including 61 million Americans, per Lancet Respiratory Medicine in 2025.
- Our leading Residential Care Software solutions are a key enabler of our Sleep and Breathing Health business, driving revenue synergies, contributing to demand generation and providing cohesion and interoperability for our AI-driven digital platform.
- Today, our Residential Care Software solutions support residential care providers serving more than 180 million individual patient accounts.
- Our quality management system is based upon the requirements of ISO 13485, Food and Drug Administration, or FDA, Quality Management System Regulation, or QMSR, European Medical Device Regulation, or MDR, the Medical Device Directive (93/42/EEC) and other applicable regulations for the markets in which we sell.
Partnerships
- In 2025, we also acquired VirtuOx, an independent diagnostic testing facility, to expand our ability to partner with healthcare providers and to help streamline the diagnostic process, while expanding collaboration with home medical equipment providers to efficiently support patients to start treatment. • Accelerate Market Growth through Awareness.
- The current impact of global tariffs is dynamic, however, new or increased tariffs, reciprocal tariffs, or other disruptions to global trade could have a material impact on our business and financial results through interruption of supply chains, increases in our costs or reduction in the availability of key inputs as our suppliers deal with an uncertain global trade environment, increases in transportation costs, or disruption of global shipping.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| COO | The Cooper Companies, Inc. | USD 69.59 | ▼ 0.2% |
| STE | STERIS plc (Ireland) | USD 224.59 | ▼ 2.5% |
| MTD | Mettler-Toledo International, I | USD 1,345.26 | ▼ 1.64% |
| IDXX | IDEXX Laboratories, Inc. | USD 535.38 | ▼ 0.67% |
| TFX | Teleflex Incorporated | USD 138.36 | ▼ 1.85% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 11:03 UTC. This page is informational and not investment advice.